Top Biotech Stocks To Buy For 2019

Zacks Investment Research upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a hold rating in a research note released on Tuesday morning.

According to Zacks, “Achillion reported wider than expected loss in the first quarter. The company has no approved product in its portfolio and focuses on developing small molecule therapeutics to treat infectious and complement-mediated diseases. The company’s pipeline mainly comprises of factor D inhibitor candidates. Though this area has commercial opportunity, the complement-mediated space is highly crowded as many biotech companies are working on bringing these treatments to market. In a major setback, J&J terminated its HCV agreement in September 2017 and Achillion lost a strong and experienced partner and major source of funds. However, the lead candidate, ACH-4471 has shown clinically meaningful complement inhibition of factor D in PNH patients. The restructuring initiative is expected to save $10 million in 2018. Moreover, shares have outperformed the industry so far this year.”

Top Biotech Stocks To Buy For 2019: Ascendis Pharma A/S(ASND)

Advisors’ Opinion:

  • [By Logan Wallace]

    Ascendis Pharma (NASDAQ:ASND) saw some unusual options trading activity on Monday. Investors purchased 1,979 call options on the stock. This is an increase of approximately 1,377% compared to the typical volume of 134 call options.

  • [By Chris Lange]

    Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.78, with a consensus analyst target of $80.17 and a 52-week range of $22.25 to $76.29.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    There was also a mixed bag of other suggestions — Rashmi Kwatra, the founder of Sixteenth Street Capital, liked Brac Bank, which is listed on the Dhaka stock market in Bangladesh. It is the 12th largest bank in Bangladesh, but the most profitable with the highest credit rating. John Khoury of Long Point Capital LP sees a 50% upside at homebuilder D.R. Horton (DHI)  and Oleg Nodelman likes U.S. biotech firm Ascendis Pharma. (ASND)

  • [By Chris Lange]

    Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.52, with a consensus analyst target price of $84.66 and a 52-week trading range of $25.50 to $76.29.

Top Biotech Stocks To Buy For 2019: Buffalo Wild Wings Inc.(BWLD)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Dave & Busters Entertainmenttripling in valuebefore falling back whilesmall cap upscale gentlemen’s clubs and restaurant ownerRCI Hospitality Holdings, Inc (NASDAQ: RICK) began taking off in 2016 and small capBuffalo Wild Wings (NASDAQ: BWLD) is being acquired by Arbys Restaurant Group:

  • [By Steve Symington]

    That’s not to say it was a quiet day for every stock on the market. With earnings season ramping up, brewing giant Anheuser-Busch InBev (NYSE:BUD) and restaurant chain Buffalo Wild Wings (NASDAQ:BWLD) served as an exercise in contrast as investors reacted to their respective quarterly reports.

Top Biotech Stocks To Buy For 2019: MediWound Ltd.(MDWD)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Mediwound (MDWD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Money Morning Staff Reports]

    After looking at this week’s penny stock gainers, we’ll give you that leg up with one of our top-rated penny stocks from our proprietary stock ranking system…

    Penny Stock Current Share Price (March 26) Last Week’s Gain
    Cartesian Inc. (OTCMKTS: CRTN) $0.39 170.69%
    Odyssey Marine Exploration Inc. (Nasdaq: OMEX) $8.76 135.90%
    iFresh Inc. (Nasdaq: IFMK) $8.25 64.64%
    China Auto Logistics Inc. (Nasdaq: CALI) $4.68 47.43%
    National American University Holdings Inc. (Nasdaq: NAUH) $1.20 39.29%
    Document Security Systems Inc. (NYSE: DSS) $1.58 33.91%
    Blonder Tongue Labs Inc. (NYSE: BDR) $0.77 33.90%
    CareDx Inc. (Nasdaq: CDNA) $7.49 29.88%
    Mediwound Ltd. (Nasdaq: MDWD) $5.10 26.51%
    New York & Co. Inc. (NYSE: NWY) $3.37 26.35%

    Don’t Miss This Shot at a $78,000 Windfall: This tiny firm is about to make the entire world wire-free. As its game-changing technology revolutionizes the global power structure, its stock could hand investors a massive return. Learn more…

  • [By Ethan Ryder]

    Mediwound (NASDAQ: MDWD) and True Drinks (OTCMKTS:TRUU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Leave a Reply

Your email address will not be published. Required fields are marked *